SIC
PBYI icon

SJS Investment Consulting’s Puma Biotechnology PBYI Stock Holding History

SJS Investment Consulting’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$422 Buy
52
+9
+21% +$66 ﹤0.01% 2316
2026
Q1 		$275 Buy
43
+7
+19% +$45 ﹤0.01% 1917
2025
Q4 		$215 Buy
+36
New +$191 ﹤0.01% 1786

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's PBYI Position: Q2 2026 in Review

SJS Investment Consulting increased its Puma Biotechnology (PBYI) stake by 21% in Q2 2026, buying an estimated $66 and bringing the position to 52 shares worth $422. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

SJS Investment Consulting first reported a position in PBYI in Q4 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • SJS Investment Consulting held 52 shares of Puma Biotechnology worth $422 as of Q2 2026.
  • SJS Investment Consulting bought 9 Puma Biotechnology shares in Q2 2026, an estimated $66.
  • Puma Biotechnology made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2316 holding.
  • SJS Investment Consulting first reported a position in Puma Biotechnology in Q4 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.